Nanobiotix (ENXTPA:NANO) is back in focus after half year 2026 figures showed sales of €3.64 million and revenue of €5.55 million, alongside a widened net loss of €34.29 million.
Investors have reacted sharply to the weaker half year revenue and wider loss. Nanobiotix has shown a 30 day share price return of down 32.72% and a 90 day move of down 32.56%. This comes even though the year to date share price return is up 18.63% and the 1 year total shareholder return is 23.71%.
Spot opportunities beyond Nanobiotix by scanning a hand-picked 614 high quality undiscovered gems that could be flying under the radar while this stock digests its latest earnings and leadership shift.After a one month slide and a wide half year loss, Nanobiotix now trades far below both analyst targets and some intrinsic value estimates. Does that gap signal mispricing, or a rational mark down of risk?
Most Popular Narrative: 57% Undervalued
Nanobiotix closed at €22.54, while the most followed narrative points to a fair value of €52.20. This frames the recent sell off in a very different light.
Reduced funding obligations for the NANORAY 312 Phase III study plus up to $71 million of nondilutive royalty financing from Healthcare Royalty Partners extend cash visibility into early 2028, allowing planned clinical and business milestones to be pursued with fewer equity raises and clearer visibility on net loss and cash burn.
See why 3 investors see Nanobiotix as 57% undervalued.
Result: Fair Value of €52.20 (UNDERVALUED)
Still, the Nanobiotix story hinges on sensitive trial outcomes and the Johnson & Johnson partnership, where weaker data or reduced commitment could quickly erode this valuation gap.
Find out about the key risks to this Nanobiotix narrative.
Next Steps
Sentiment around Nanobiotix is clearly split, with concern about risks on one side and optimism about potential rewards on the other. Move quickly, review the full picture, and weigh both the 2 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Nanobiotix?
Do not stop with Nanobiotix. Use fresh screeners to surface new opportunities that fit your style, strengthen your watchlist, and keep you ahead of slower movers.
- Target resilient payouts by scanning a focused mix of income ideas with the 165 dividend fortresses that can help anchor your portfolio with cash returns.
- Prioritise financial strength and filter for sturdier balance sheets through a curated list of solid balance sheet and fundamentals (206 results) so you are not guessing on basic resilience.
- Hunt for potential future winners early by running a 121 elite penny stocks with strong financials before others start paying attention to the same tickers.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com